| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/12/2013 | US8372895 Biomaterial containing degradation stabilized polymer |
| 02/12/2013 | US8372821 Stable aqueous compositions comprising bioactive creatine species |
| 02/12/2013 | US8372818 Targeted double stranded RNA mediated cell killing |
| 02/12/2013 | US8372805 Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects |
| 02/12/2013 | US8372800 Albumin-free factor VIII formulations |
| 02/12/2013 | US8372798 A stable antibody liquid comprising a precipitated immunoglobulins and water; precipitating with a biocompatible polymer; storage stability |
| 02/12/2013 | US8372428 Chewable soft capsule having improved ingestion property and method for producing same |
| 02/12/2013 | US8372426 Dietary fiber composition |
| 02/12/2013 | US8372424 Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
| 02/12/2013 | US8372422 Hydroxyapatite-targeting poly(ethylene glycol) and related polymers |
| 02/12/2013 | US8372413 Mycobacterial disease, malaria, leishmaniasis, toxoplasmosis, schistosomiasis and clonorchiasis; antiallergens; asthma |
| 02/12/2013 | US8372388 Method for preparing a stable TNF-α vaccine |
| 02/12/2013 | CA2694238C Pharmaceutical aerosol compositions comprising fluticasone |
| 02/12/2013 | CA2665707C Method for identification of cellular protein antigens and presence of antibodies to specific cellular protein antigens in serum |
| 02/12/2013 | CA2580577C Amitraz compositions |
| 02/12/2013 | CA2567827C Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons |
| 02/12/2013 | CA2545362C Assembly of gas-filled microvesicle with active component for contrast imaging |
| 02/12/2013 | CA2535013C Micro-particle fatty acid salt solid dosage formulations for therapeutic agents |
| 02/12/2013 | CA2510813C Injectable pharmaceutical compositions comprising sodium diclofenac and .beta.-cyclodextrin |
| 02/12/2013 | CA2492089C Delivery system for pharmaceutical agents |
| 02/12/2013 | CA2477350C Novel crystalline forms of the anti-cancer compound zd1839 |
| 02/12/2013 | CA2462646C Adjuvanted meningococcus compositions |
| 02/12/2013 | CA2388450C Tadg-15: an extracellular serine protease overexpressed in carcinomas |
| 02/12/2013 | CA2366880C Compositions of polyacids and polyethers and methods for their use in reducing adhesions |
| 02/07/2013 | WO2013020136A2 Treatment of traumatic brain injury |
| 02/07/2013 | WO2013020074A2 A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin |
| 02/07/2013 | WO2013020040A2 Radiated cancer cells as a vehicle for cancer nanotherapy |
| 02/07/2013 | WO2013020005A2 Oxazoline polymer compositions and use thereof |
| 02/07/2013 | WO2013019930A2 Decomposable apparatus and methods for fabricating same |
| 02/07/2013 | WO2013019917A2 Permanent attachment of ammonium and guanidine-based antimicrobials to surfaces containing c-h functionality |
| 02/07/2013 | WO2013019733A2 Methods, compositions and kits for therapeutic treatment with wet spun microstructures |
| 02/07/2013 | WO2013019681A2 Selective delivery molecules and methods of use |
| 02/07/2013 | WO2013019669A2 Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses |
| 02/07/2013 | WO2013019658A2 Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents |
| 02/07/2013 | WO2013019648A1 Control of antibody responses to synthetic nanocarriers |
| 02/07/2013 | WO2013019090A1 Hydrophilic nanoparticles surface-modified with monosaccharide phosphate or monosaccharide phosphate derivatives, its colloidal solution and use thereof |
| 02/07/2013 | WO2013019049A1 Complex comprising steviol glycosides orlicorice root, and poorly soluble material |
| 02/07/2013 | WO2013019024A1 Preparation for oral administration with improved bioavailability of megestrol acetate, and method for improving bioavailability of megestrol acetate preparation for oral administration |
| 02/07/2013 | WO2013018889A1 Cancer treatment and/or prevention drug composition |
| 02/07/2013 | WO2013018837A1 Left ventricular diastolic function improving agent |
| 02/07/2013 | WO2013018765A1 Pharmaceutical composition containing loxoprofen |
| 02/07/2013 | WO2013018035A1 Pharmaceutical composition comprising factor vii encapsulated in micelles |
| 02/07/2013 | WO2013018008A1 Basic alpha lipoic acid solution and its uses |
| 02/07/2013 | WO2013017631A1 Kisspeptide-pentasaccharide conjugates |
| 02/07/2013 | WO2013017571A1 Aqueous solutions of lipophilic substances, in particular medicinal solutions |
| 02/07/2013 | WO2013017540A1 Combination therapy for the treatment of cd19+ b-cell malignancies symptoms comprising an anti-cd19 maytansinoid immunoconjugate and rituximab |
| 02/07/2013 | WO2013017494A1 Pharmaceutical composition of oxidised avidin suitable for inhalation |
| 02/07/2013 | WO2013017100A1 Imatinib mesylate tablet |
| 02/07/2013 | WO2012165815A3 Nano-vehicle derived from tumor tissue, and cancer vaccine using same |
| 02/07/2013 | WO2012156997A3 Multi-particulate pharmaceutical composition |
| 02/07/2013 | WO2012138379A3 Multifunctional chelator-free radioactive nanoparticles for imaging and therapy |
| 02/07/2013 | WO2011106297A3 Compositions and methods for the diagnosis and treatment of tumor |
| 02/07/2013 | US20130035754 Drug-delivery endovascular stent and method of forming the same |
| 02/07/2013 | US20130035403 Cells, nucleic acids, enzymes and use thereof, and methods for the production of sophorolipids |
| 02/07/2013 | US20130035402 Bioabsorbable polyesteramides and uses thereof |
| 02/07/2013 | US20130035401 Novel self-reversible reverse latex, and use thereof as a thickening agent in a cosmetic composition |
| 02/07/2013 | US20130035399 Marked inorganic additives |
| 02/07/2013 | US20130035279 Method and a system for producing thermolabile nanoparticles with controlled properties and nanoparticles matrices made thereby |
| 02/07/2013 | US20130035235 Polyurethane dispersions for sealing the teats of the mammary glands in milking animals |
| 02/07/2013 | US20130034538 Reverse hexagonal mesophases (hii) and uses thereof |
| 02/07/2013 | US20130034533 High Molecular Weight Derivatives of Vitamin K-Dependent Polypeptides |
| 02/07/2013 | CA2844152A1 Stable anti-inflammatory solutions for injection |
| 02/07/2013 | CA2844034A1 Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| 02/07/2013 | CA2843274A1 Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses |
| 02/07/2013 | CA2843139A1 Corticosteroids for the treatment of joint pain |
| 02/07/2013 | CA2842906A1 Left ventricular diastolic function improving agent |
| 02/07/2013 | CA2842802A1 Non-digestible capsules for the delivery of fluid absorbing materials |
| 02/07/2013 | CA2842276A1 Pharmaceutical composition of oxidised avidin suitable for inhalation |
| 02/07/2013 | CA2841249A1 Selective delivery molecules and methods of use |
| 02/06/2013 | EP2554185A1 Coating fat composition and particulate composition using same |
| 02/06/2013 | EP2554183A1 Pharmaceutical composition comprising a GLP-1-agonist, an insulin, and methionine |
| 02/06/2013 | EP2554169A1 Pharmaceutical preparation comprising phenylalanine derivative |
| 02/06/2013 | EP2554161A1 Pharmaceutical composition comprising factor VII encapsulated in micelles |
| 02/06/2013 | EP2554160A1 Method for preparing an enriched IgG composition from plasma |
| 02/06/2013 | EP2554042A1 Water-soluble iron supply agent with reducing power and with coffee grounds or tea dregs as raw material |
| 02/06/2013 | EP2553019A1 Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
| 02/06/2013 | EP2553000A1 Supercritical fluid treatment of high molecular weight biopolymers |
| 02/06/2013 | EP2552969A1 Injectable drug delivery formulation |
| 02/06/2013 | EP2552489A1 Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant |
| 02/06/2013 | EP2552488A1 Fusion protein and its uses |
| 02/06/2013 | EP2552487A1 Thermogelling anaesthetic compositions |
| 02/06/2013 | EP2552486A1 Transdermal delivery patch |
| 02/06/2013 | EP2552482A2 Stabilized antibody preparations and uses thereof |
| 02/06/2013 | EP2552478A1 Excipients for stabilising viral particles, polypeptides or biological material |
| 02/06/2013 | EP2552474A2 An insulin conjugate using an immunoglobulin fragment |
| 02/06/2013 | EP2552465A1 Stabilisation of viral particles |
| 02/06/2013 | EP2552458A1 Injectable dendrimer hydrogel nanoparticles |
| 02/06/2013 | EP2552443A1 Improved treatment of renal cell carcinoma |
| 02/06/2013 | EP2552438A1 Methods of treatment of hepatocellular carcinoma |
| 02/06/2013 | EP2552425A1 Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists |
| 02/06/2013 | EP2552422A2 Long-acting interferon beta formulation using immunoglobulin fragment |
| 02/06/2013 | EP2552421A2 Long-acting human follicle-stimulating hormone formulation using immunoglobulin fragment |
| 02/06/2013 | EP2552420A1 Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative |
| 02/06/2013 | EP2552416A2 Compositions and methods for improved retention of a pharmaceutical composition at a local administration site |
| 02/06/2013 | EP2552411A2 Stabilized antibody preparations and uses thereof |
| 02/06/2013 | EP2552408A2 Water-free pharmaceutical compositions suitable for local anaesthetics |
| 02/06/2013 | EP2552406A1 Photo-crosslinked gellan gum-based hydrogels: preparation methods and uses thereof |
| 02/06/2013 | EP2552403A2 A fast dissolving pharmaceutical composition |
| 02/06/2013 | EP2552402A2 Multilayer melt-extruded film |
| 02/06/2013 | EP2552195A1 Antimicrobial oil-in-water emulsion |